Baicalein Targets GTPase‐Mediated Autophagy to Eliminate Liver Tumor–Initiating Stem Cell–Like Cells Resistant to mTORC1 Inhibition
Raymond Wu, Ramachandran Murali, Yasuaki Kabe, Samuel W. French, Yi‐Ming Chiang, Siyu Liu, Linda Sher, Clay C. Wang, Stan Louie, Hidekazu Tsukamoto – 5 May 2018 – Drug resistance is a major problem in the treatment of liver cancer. Mammalian Target of Rapamycin 1 (mTORC1) inhibitors have been tested for the treatment of liver cancer based on hyperactive mTOR in this malignancy. However, their clinical trials showed poor outcome, most likely due to their ability to upregulate CD133 and promote chemoresistance.